NYSE:NVTAInVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVTA stock has increased by 81.4% and is now trading at $28.75.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) announced its quarterly earnings data on Tuesday, August, 4th. The medical research company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.15. The medical research company had revenue of $46.20 million for the quarter, compared to the consensus estimate of $39.63 million. InVitae had a negative return on equity of 82.78% and a negative net margin of 182.73%. InVitae's quarterly revenue was down 14.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.54) earnings per share.
View InVitae's earnings history.

6 Wall Street analysts have issued 12-month price objectives for InVitae's stock. Their forecasts range from $20.00 to $37.25. On average, they anticipate InVitae's stock price to reach $32.54 in the next year. This suggests a possible upside of 13.2% from the stock's current price.
View analysts' price targets for InVitae.

Headlines about NVTA stock have been trending positive this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. InVitae earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about InVitae.

Some companies that are related to InVitae include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Natera (NTRA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Biocept (BIOC), Enzo Biochem (ENZ) and Anpac Bio-Medical Science (ANPC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Square (SQ), Trade Desk (TTD), Shopify (SHOP), Walt Disney (DIS), salesforce.com (CRM), Twilio (TWLO) and Micron Technology (MU).

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (9.79%), Victory Capital Management Inc. (0.83%), Jennison Associates LLC (0.31%), Swiss National Bank (0.21%), Mutual of America Capital Management LLC (0.14%) and Profit Investment Management LLC (0.13%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., Principal Financial Group Inc., PNC Financial Services Group Inc., Profit Investment Management LLC, CAPROCK Group Inc., OTA Financial Group L.P., and Dupont Capital Management Corp. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae.

NVTA stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Fagan Associates Inc., Mackay Shields LLC, Mutual of America Capital Management LLC, Swiss National Bank, AE Wealth Management LLC, Sawtooth Solutions LLC, and First Trust Advisors LP.
View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $28.75.

InVitae has a market capitalization of $3.79 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]